Clear cell adenocarcinoma of the lung and its driver mutation

Stopsack, Konrad H.; Soltermann, Alex; Zimmermann, Anne-Katrin; Weder, Walter; Curioni-Fontecedro, Alessandra

doi:10.1016/j.ctrc.2013.04.002

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, the presence of clear metaplasia, also known as clear cell change, a phenomenon where cells lose their usual staining characteristics, adds further complexity to the narrative [ 2 , 3 ]. Clear cell change, often observed in other organs like the cervix and lungs [ 3 , 4 ], has never been documented in the gallbladder.…”

Section: Discussionmentioning

confidence: 99%

Apocrine and clear cell metaplasia in the gallbladder: the first finding in the medical literature

Al-Janabi

2024

Oxford Medical Case Reports

View full text Add to dashboard Cite

Apocrine metaplasia, specifically, involves the development of cells resembling those in apocrine glands, characterized by their distinctive cytoplasmic features. Apocrine metaplasia in the gallbladder represents a new and intriguing discovery, marking a significant milestone in medical literature. Furthermore, clear cell metaplasia is often observed in other organs like the cervix and has never been documented in the gallbladder. The coexistence of apocrine and clear metaplasia challenges existing paradigms surrounding gallbladder pathology, prompting a reevaluation of the underlying mechanisms that drive these cellular transformations.

show abstract

Section: Discussionmentioning

confidence: 99%

Apocrine and clear cell metaplasia in the gallbladder: the first finding in the medical literature

Al-Janabi

2024

Oxford Medical Case Reports

View full text Add to dashboard Cite

show abstract

Genomic and Molecular Abnormalities in Gynecologic Clear Cell Carcinoma

Marks

Brown

Dizon

2019

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Gynecologic clear cell carcinoma is a rare histology, accounting for ~5% of all ovarian and endometrial cancers in the United States. Compared to other types of gynecologic cancer, they are generally less responsive to standard therapy and have an overall worse prognosis. In addition, mounting evidence suggests that the landscape of genetic and molecular abnormalities observed in these tumors is distinct from other cancers that arise from the same sites of origin. On a molecular level, these tumors characteristically display upregulation of the PI3K-AKT-mTOR and RAS-RAF-MAPK signaling axes, frequent loss of ARID1a, and overexpression of MDM2. Evidence also suggests that these tumors are more likely to express programmed death ligand 1 or demonstrate microsatellite instability than other gynecologic cancers. Despite these important differences, there has been relatively little investigation into histology-specific treatment of clear cell gynecologic cancers, representing an opportunity for new drug development. In this article, we review the unique genetic and molecular features of gynecologic clear cell cancers with an emphasis on potential therapeutic targets. The results of completed studies of treatment for clear cell carcinoma are also presented. We conclude with a discussion of ongoing clinical trials and potential avenues for future study.

show abstract

Clinical characteristics and gene mutation analysis of clear cell tumor of the lung

Pan²,

Chen

et al. 2021

Indian Journal of Pathology and Microbiology

View full text Add to dashboard Cite

There were rare clinical reports on clear cell tumor of the lung (CCTL). The clinical characteristics and underlying genetic mutation status of CCTL are poorly understood. From 2012 to 2017, patients pathologically diagnosed with CCTL in our hospital were investigated and analyzed based on clinical manifestations, pathological characteristics, prognosis and full gene mutation status through next generation sequencing (NGS) technology. During a 6-year period, four eligible patients were diagnosed with CCTL through surgical resection and were included in this study. All patients showed solitary nodules or lumps located in the left lung. The average maximum diameter of lesions was 2.5 ± 1.1 cm. Computed tomography (CT) imaging characteristics of these nodules/lumps demonstrated the features of benign tumors. The hematoxylin-eosin (HE) morphology and immunohistochemistry were consistent with the histopathological features of benign CCTL. Subsequent NGS analysis showed frame shift mutations of F2421/E2419, K1466E mutation, and p. 1450_1456 deletion mutation in mTOR gene in two of four patient samples and amplifications of MCL1 were observed in three of four samples. CCTL is a rare type of primary pulmonary mesenchymal tumor with good prognosis. Preliminary diagnosis on CT is usually sclerosing pneumocytoma. It is still unclear whether the occurrence and development of the disease are related to specific gene mutation. In this study, the genomic findings of frame shift mutation of mTOR genes and amplification of MCL1 gene in CCTL suggest that these mutations might play a role in proliferation of CCTL.

show abstract

Clear cell adenocarcinoma of the lung and its driver mutation

Cited by 3 publications

References 9 publications

Apocrine and clear cell metaplasia in the gallbladder: the first finding in the medical literature

Apocrine and clear cell metaplasia in the gallbladder: the first finding in the medical literature

Genomic and Molecular Abnormalities in Gynecologic Clear Cell Carcinoma

Clinical characteristics and gene mutation analysis of clear cell tumor of the lung

Contact Info

Product

Resources

About